Nav: Home

AHA, Verily Life Sciences, AstraZeneca announce winner of $75M One Brave Idea research award

October 05, 2016

DALLAS, TX and SOUTH SAN FRANCISCO, CA, October 5, 2016 - The American Heart Association (AHA), Verily Life Sciences LLC (formerly Google Life Sciences), an Alphabet company, and AstraZeneca, today announced that the One Brave Idea™ research award will be granted to Dr. Calum MacRae, chief of Cardiovascular Medicine at Boston's Brigham and Women's Hospital, to support his visionary approach to understanding and addressing coronary heart disease (CHD) and its devastating consequences.

"After launching a global search effort earlier this year, we are proud to announce the selection of Dr. Calum MacRae as the leader of our One Brave Idea initiative," said Nancy Brown, chief executive officer of the American Heart Association. "Dr. MacRae and his newly-formed, world-renowned, multidisciplinary team were selected from among hundreds of applicants throughout the world to receive this landmark award that will provide support over a five-year period for a research project focused on uncovering the causes of heart disease, including previously unrecognized signals marking the transition from wellness to the earliest, yet still largely invisible stages of disease."

"The vision for One Brave Idea was to create an innovative model for scientific research by bringing together significant resources and diverse organizations to support a single vision," said Dr. Jessica Mega, chief medical officer of Verily. "With our partners at the American Heart Association and AstraZeneca, we hope this initiative will inspire other new approaches to funding and catalyze meaningful advances for patients living with coronary heart disease and other conditions."

The AHA, Verily and AstraZeneca launched One Brave Idea in January 2016 as the largest one-time award to a single team to find a cure to end CHD and its consequences. In addition to receiving funding, Dr. MacRae and his team will have access to the combined expertise and resources of the three partner organizations, which include the AHA's medical and scientific prowess, Verily's technical expertise in device engineering, data analytics and software development for clinical applications, and AstraZeneca's scientific insights and mentoring.

"AstraZeneca, AHA and Verily share a common purpose and passion for patients and science. We believe that this collaboration will ignite and inspire ideas, opening the door to find a big, brave solution," said Dr. Greg Keenan, vice president and head of US Medical Affairs of AstraZeneca. "Dr. MacRae's research not only has the potential to advance our understanding of coronary heart disease and its underlying consequences, but also allows us to combine resources to take a truly innovative and multidisciplinary approach in addressing cardiovascular disease."

"I'm grateful to the AHA, Verily and AstraZeneca for believing in my research vision and showing their support by selecting our remarkable team as the recipients of the One Brave Idea award," said Dr. MacRae. "The earliest indicators of coronary heart disease remain unknown, both on a genetic and molecular level. If we unearth and characterize novel markers in people genetically prone to heart disease or with early stages of the disease, we can potentially screen the broader population at a younger age to identify those same markers and discover preventative or pre-disease interventions that can break the cascade towards disease."
-end-
LIVE Virtual Press Conference

Dr. MacRae and representatives from the AHA, Verily and AstraZeneca will be hosting a virtual press conference via YouTube Live, today, October 5, 2016 at 2:30 pm ET/11:30 am PT to provide additional details around One Brave Idea and the winning research project.

To participate in the press conference, click https://www.youtube.com/watch?v=ZPTnKzTdUj8

The presentation will be archived on YouTube following the event.

About the American Heart Association

The American Heart Association is devoted to saving people from heart disease and stroke - America's No. 1 and No. 5 killers. We team with millions of volunteers to fund innovative research, fight for stronger public health policies, and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation's oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.

About Verily Life Sciences

Verily is a life sciences research and engineering organization focused on improving healthcare outcomes by applying the latest scientific and technological advances to significant problems in health and biology. By combining unparalleled capabilities in data organization and analytics services with robust scientific and product engineering expertise, Verily is targeting the dual objectives of creating tools and user-friendly platforms that capture a deeper and broader set of health data, and organizing the data so that it is useful and actionable. Verily partners with leading life sciences, medical device, and government organizations to leverage deep domain expertise and resources that enable exponentially faster development, meaningful advancements, and deployment at scale.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in Inflammation, Infection and Neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: http://www.astrazeneca-us.com.

Media Contacts:

American Heart Association - Alex Barbieri, (214) 783-7751, alex.barbieri@heart.org

Verily - Dan Budwick, Pure Communications, Inc., (973) 271-6085, dan@purecommunicationsinc.com

AstraZeneca - Michele Meixell, (302) 885-2677

American Heart Association

Related Heart Disease Articles:

Where you live could determine risk of heart attack, stroke or dying of heart disease
People living in parts of Ontario with better access to preventive health care had lower rates of cardiac events compared to residents of regions with less access, found a new study published in CMAJ (Canadian Medical Association Journal).
Older adults with heart disease can become more independent and heart healthy with physical activity
Improving physical function among older adults with heart disease helps heart health and even the oldest have a better quality of life and greater independence.
Dietary factors associated with substantial proportion of deaths from heart disease, stroke, and disease
Nearly half of all deaths due to heart disease, stroke, and type 2 diabetes in the US in 2012 were associated with suboptimal consumption of certain dietary factors, according to a study appearing in the March 7 issue of JAMA.
Certain heart fat associated with higher risk of heart disease in postmenopausal women
For the first time, researchers have pinpointed a type of heart fat, linked it to a risk factor for heart disease and shown that menopausal status and estrogen levels are critical modifying factors of its associated risk in women.
Maternal chronic disease linked to higher rates of congenital heart disease in babies
Pregnant women with congenital heart defects or type 2 diabetes have a higher risk of giving birth to babies with severe congenital heart disease and should be monitored closely in the prenatal period, according to a study published in CMAJ.
Novel heart valve replacement offers hope for thousands with rheumatic heart disease
A novel heart valve replacement method is revealed today that offers hope for the thousands of patients with rheumatic heart disease who need the procedure each year.
Younger heart attack survivors may face premature heart disease death
For patients age 50 and younger, the risk of premature death after a heart attack has dropped significantly, but their risk is still almost twice as high when compared to the general population, largely due to heart disease and other smoking-related diseases The risk of heart attack can be greatly reduced by quitting smoking, exercising and following a healthy diet.
Citrus fruits could help prevent obesity-related heart disease, liver disease, diabetes
Oranges and other citrus fruits are good for you -- they contain plenty of vitamins and substances, such as antioxidants, that can help keep you healthy.
Gallstone disease may increase heart disease risk
A history of gallstone disease was linked to a 23 percent increased risk of developing coronary heart disease.
Americans are getting heart-healthier: Coronary heart disease decreasing in the US
Coronary heart disease is one of the leading causes of death in the United States.

Related Heart Disease Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".